SLC5A2 and Alport syndrome: Preclinical studies in Alport syndrome models have shown that dual SGLT2 and mineralocorticoid receptor inhibition synergistically attenuates glomerulosclerosis and tubulointerstitial fibrosis, preserving renal architecture more effectively than either agent alone [16].